Larimar Therapeutics (LRMR) Competitors $3.87 -0.07 (-1.78%) Closing price 09/4/2025 04:00 PM EasternExtended Trading$3.91 +0.04 (+1.03%) As of 05:58 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock LRMR vs. CALT, SPRY, PHVS, RCUS, ZYME, GPCR, CRMD, LENZ, SION, and STOKShould you be buying Larimar Therapeutics stock or one of its competitors? The main competitors of Larimar Therapeutics include Calliditas Therapeutics AB (publ) (CALT), ARS Pharmaceuticals (SPRY), Pharvaris (PHVS), Arcus Biosciences (RCUS), Zymeworks (ZYME), Structure Therapeutics (GPCR), CorMedix (CRMD), LENZ Therapeutics (LENZ), Sionna Therapeutics (SION), and Stoke Therapeutics (STOK). These companies are all part of the "pharmaceutical products" industry. Larimar Therapeutics vs. Its Competitors Calliditas Therapeutics AB (publ) ARS Pharmaceuticals Pharvaris Arcus Biosciences Zymeworks Structure Therapeutics CorMedix LENZ Therapeutics Sionna Therapeutics Stoke Therapeutics Larimar Therapeutics (NASDAQ:LRMR) and Calliditas Therapeutics AB (publ) (NASDAQ:CALT) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, media sentiment, risk, valuation, institutional ownership, analyst recommendations and earnings. Does the media favor LRMR or CALT? In the previous week, Larimar Therapeutics had 1 more articles in the media than Calliditas Therapeutics AB (publ). MarketBeat recorded 1 mentions for Larimar Therapeutics and 0 mentions for Calliditas Therapeutics AB (publ). Larimar Therapeutics' average media sentiment score of 1.67 beat Calliditas Therapeutics AB (publ)'s score of 0.00 indicating that Larimar Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Larimar Therapeutics Very Positive Calliditas Therapeutics AB (publ) Neutral Do institutionals & insiders believe in LRMR or CALT? 91.9% of Larimar Therapeutics shares are held by institutional investors. Comparatively, 2.8% of Calliditas Therapeutics AB (publ) shares are held by institutional investors. 4.5% of Larimar Therapeutics shares are held by insiders. Comparatively, 2.2% of Calliditas Therapeutics AB (publ) shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. Do analysts prefer LRMR or CALT? Larimar Therapeutics presently has a consensus price target of $18.43, indicating a potential upside of 376.19%. Given Larimar Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Larimar Therapeutics is more favorable than Calliditas Therapeutics AB (publ).Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Larimar Therapeutics 0 Sell rating(s) 0 Hold rating(s) 9 Buy rating(s) 0 Strong Buy rating(s) 3.00Calliditas Therapeutics AB (publ) 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Is LRMR or CALT more profitable? Larimar Therapeutics has a net margin of 0.00% compared to Calliditas Therapeutics AB (publ)'s net margin of -30.18%. Larimar Therapeutics' return on equity of -62.92% beat Calliditas Therapeutics AB (publ)'s return on equity.Company Net Margins Return on Equity Return on Assets Larimar TherapeuticsN/A -62.92% -53.98% Calliditas Therapeutics AB (publ) -30.18%-212.04%-27.96% Which has more volatility & risk, LRMR or CALT? Larimar Therapeutics has a beta of 0.91, indicating that its share price is 9% less volatile than the S&P 500. Comparatively, Calliditas Therapeutics AB (publ) has a beta of 1.77, indicating that its share price is 77% more volatile than the S&P 500. Which has stronger earnings & valuation, LRMR or CALT? Calliditas Therapeutics AB (publ) has higher revenue and earnings than Larimar Therapeutics. Calliditas Therapeutics AB (publ) is trading at a lower price-to-earnings ratio than Larimar Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioLarimar TherapeuticsN/AN/A-$80.60M-$1.56-2.48Calliditas Therapeutics AB (publ)$1.60B0.74-$43.96M-$1.85-21.62 SummaryLarimar Therapeutics beats Calliditas Therapeutics AB (publ) on 11 of the 15 factors compared between the two stocks. Get Larimar Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for LRMR and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding LRMR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart LRMR vs. The Competition Export to ExcelMetricLarimar TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$326.14M$2.55B$5.76B$9.85BDividend YieldN/A49.35%6.67%4.51%P/E Ratio-2.4822.9075.7126.43Price / SalesN/A714.55548.17119.09Price / CashN/A169.7737.0558.92Price / Book1.445.3911.296.06Net Income-$80.60M$32.95M$3.29B$266.28M7 Day Performance6.91%1.08%0.18%-0.32%1 Month Performance3.48%6.32%6.30%3.44%1 Year Performance-56.52%-0.28%56.91%23.11% Larimar Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)LRMRLarimar Therapeutics3.1064 of 5 stars$3.87-1.8%$18.43+376.2%-50.2%$326.14MN/A-2.4830Positive NewsCALTCalliditas Therapeutics AB (publ)N/A$40.00flatN/AN/A$1.19B$1.60B-21.62180SPRYARS Pharmaceuticals3.0038 of 5 stars$11.62-9.6%$31.00+166.8%-10.4%$1.15B$89.15M-23.7190News CoveragePositive NewsAnalyst ForecastHigh Trading VolumePHVSPharvaris2.5658 of 5 stars$21.65-5.2%$35.60+64.4%+27.0%$1.13BN/A-6.4430News CoverageRCUSArcus Biosciences2.0733 of 5 stars$10.60-0.1%$21.14+99.6%-29.1%$1.13B$258M-3.34500News CoveragePositive NewsZYMEZymeworks0.1136 of 5 stars$14.81-0.2%N/AN/A$1.11B$76.30M-15.27460GPCRStructure Therapeutics2.5603 of 5 stars$19.30+0.8%$75.71+292.3%-47.8%$1.11BN/A-18.38136Positive NewsCRMDCorMedix3.551 of 5 stars$14.83+3.3%$17.33+16.9%+123.0%$1.11B$43.47M19.7730Positive NewsShort Interest ↑LENZLENZ Therapeutics1.1013 of 5 stars$38.63+1.1%$49.60+28.4%+61.5%$1.10BN/A-20.33110Positive NewsSIONSionna TherapeuticsN/A$24.62-4.3%$38.50+56.4%N/A$1.09BN/A0.0035News CoverageAnalyst ForecastInsider TradeSTOKStoke Therapeutics4.5997 of 5 stars$19.76-0.1%$25.57+29.4%+26.7%$1.08B$36.56M23.25100News CoverageInsider Trade Related Companies and Tools Related Companies Calliditas Therapeutics AB (publ) Alternatives ARS Pharmaceuticals Alternatives Pharvaris Alternatives Arcus Biosciences Alternatives Zymeworks Alternatives Structure Therapeutics Alternatives CorMedix Alternatives LENZ Therapeutics Alternatives Sionna Therapeutics Alternatives Stoke Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:LRMR) was last updated on 9/5/2025 by MarketBeat.com Staff From Our Partners“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | SponsoredHow “Trump’s New Dollar” Could Impact Your WealthPresident Trump just signed a game-changing law… That could soon upgrade the U.S. dollar in your checking a...Brownstone Research | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | SponsoredWhat's the Best Way to Lower RMD Taxes?Turning 73 triggers a key IRS rule: you must begin taking required minimum distributions (RMDs) from certain r...SmartAsset | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | SponsoredOne tiny company just cracked Google’s $19B problemFor decades, this “AI metal” was trapped in labs, too slow and expensive to ever reach mass production. The...True Market Insiders | SponsoredWarren Buffett Issues Cryptic Warning on U.S. DollarImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Larimar Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Larimar Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free LRMR Stock Alerts